Partner MedImmune expands colorectal cancer patient cohort in ongoing Phase I trial evaluating monalizumab in combination with Imfinzi® (durvalumab)
Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018
Innate Pharma Hosts R&D Day Today in London
2017: clinical progress, portfolio expansion and financial strength create the foundation for future growth
In Memoriam Alessandro Moretta
Innate Pharma and MedImmune enter clinical trial collaboration
Prof. Jean-Yves Blay appointed to the Innate Pharma Supervisory Board
World renowned immunologist, professor Eric Vivier, joins Innate Pharma as Chief Scientific Officer
Number of shares and voting rights of Innate Pharma as at January 1, 2018
Upcoming investor conferences
